Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to investigate the safety of Umbilical Cord Blood Plasma infusions in elderly adults regardless of gender, with age-related cognitive decline. Human clinical data of the use of young plasma appear to show beneficial cognitive effects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Umbilical Cord Plasma Infusion | Experimental | Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Umbilical Cord Blood Plasma | Biological | Intravenous Infusion of Umbilical Cord Blood Plasma |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety of Umbilical Cord Blood Plasma Infusion | Assessment of Human Leukocyte Antigen (HLA) in recipient following Umbilical Cord Blood Plasma infusion | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of Executive Function | Assessment of executive function by Wisconsin Card Sorting Test (WCST) | 12 months |
| Assessment of Working Memory | Assessment of working memory by Wechsler Memory Scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients receiving any other investigational biologics or drugs
History of transfusion reaction
Dementia related to specific pathology (Alzheimer's Disease, Alcohol-related, etc.)
Inability to participate in cognitive or performance testing
History of cancer in the last 5 years
History of infectious disease within the previous 12 months
Severe kidney (eGFR< 30) and heart failure (Class III/IV)
History of Human Immunodeficiency Virus Infection
History of Hepatitis B, or C
History of immunosuppressive therapy
History of organ transplantation
Difficulty of obtaining peripheral venous access
Allergy to histamine blockers
Inability to participate in the clinical trial at any data collection and end points
-
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28815019 | Background | Horowitz AM, Villeda SA. Therapeutic potential of systemic brain rejuvenation strategies for neurodegenerative disease. F1000Res. 2017 Aug 1;6:1291. doi: 10.12688/f1000research.11437.1. eCollection 2017. | |
| 21886162 | Background | Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011 Aug 31;477(7362):90-4. doi: 10.1038/nature10357. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 months |
| 32054965 | Background | Kang S, Moser VA, Svendsen CN, Goodridge HS. Rejuvenating the blood and bone marrow to slow aging-associated cognitive decline and Alzheimer's disease. Commun Biol. 2020 Feb 13;3(1):69. doi: 10.1038/s42003-020-0797-4. |
| 24793238 | Background | Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, Wyss-Coray T. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014 Jun;20(6):659-63. doi: 10.1038/nm.3569. Epub 2014 May 4. |